Our team of leading scientists and clinicians has pioneered many advances that have become standards of care, leading to improved survival rates.
The Myeloma Center is known for its “bench to bedside” approach, continually translating advances in the laboratory into breakthrough clinical treatments. The quality of our innovative clinical and basic science research is highly regarded throughout the world.
The Myeloma Center routinely uses advanced diagnostics, such as Gene Array Analysis and DNA Sequencing, for determining optimal care management and planning therapy. Advanced diagnostics enable us to identify the specifics of each patient’s disease and personalize a course of treatment for the best possible results.
Making Cure a Reality
We are committed to:
- Accelerating curative therapies for multiple myeloma and related diseases through an integrated program of innovative research and high-quality, comprehensive patient care
- Customizing care based on each patient’s genetic profile and risk factors for truly personalized treatment
- Pushing the envelope of understanding and discovery to unravel the biology of myeloma and maximize cure
The Myeloma Center also includes a focus on the prevention and management of potential treatment-related consequences, such as myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML).
The Myeloma Center is committed to accelerating curative therapies for Multiple Myeloma and related diseases through an integrated program of innovative research and high-quality, comprehensive patient care.
Benefits of our High Patient Volumes
More than 11,750 patients from every state in the United States and more than 50 foreign countries have chosen to come to the Myeloma Center for their care.We have performed more stem cell transplants for myeloma than any other center in the world.
With a disease as complex as myeloma, a large patient volume offers distinct advantages.
- Our large patient volume supports a program of clinical trials that enable patients to benefit from innovative, cutting-edge care.
- Our large patient volume supports statistical validity of data. We have a comprehensive database with detailed baseline and follow-up information that is unsurpassed and is used to predict patient outcome.
- Our staff is truly focused on the treatment of patients with multiple myeloma and related diseases. Physicians, nurses and other members of our patient care team are thoroughly familiar with treatment processes and the sequence of treatments, and are skilled at anticipating and recognizing potential complications and addressing patient and family needs.
Our Academic Home
The Myeloma Center is a Chancellor’s Center of Excellence at the University of Arkansas for Medical Sciences (UAMS). The UAMS Campus includes a 350-bed teaching hospital, the Jackson T. Stephens Spine & Neurosciences Institute, the Winthrop P. Rockefeller Cancer Institute, the Harvey and Bernice Jones Eye Institute, the Outpatient Center, and the Donald W. Reynolds Center on Aging. UAMS is the only academic medical center in the state. It includes Colleges of Medicine, Nursing, Health Professions, Pharmacy, and Public Health, as well as a Graduate School. Myeloma Center physicians are faculty members of the UAMS College of Medicine.
The Myeloma Center is housed in the Winthrop P. Rockefeller Cancer Institute (Cancer Institute). Filled with natural light, the Cancer Institute environment promotes comfort and convenience for patients, caregivers and families, and collaboration opportunities for physicians, scientists and other health care professionals.
The Myeloma Center’s research laboratories feature the latest and most scientifically sophisticated equipment.
A 30-bed inpatient unit in the hospital is dedicated to the multiple myeloma/stem cell transplant service. Spacious rooms include large picture windows and comfortable seating for family members and caregivers. Specially trained nursing and support staff meet the individual needs of each patient.
The Myeloma Center Advisory Board
The Myeloma Center Advisory Board assists the Myeloma Center with cultivating the resources necessary to expand its clinical, research, and educational programs focused on continued development of curative therapies for multiple myeloma and related diseases.
Carol Ammon of Wilmington, Delaware, serves as chairman of the board.